Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients

Imatinib mesylate (IM) is highly efficacious in the treatment of chronic myeloid leukemia (CML). Therapeutic drug monitoring and pharmacogenetic screening are affirmed for better management of IM therapy. The goal of this study was to gain a greater mechanistic understanding of the factors controlli...

Descripción completa

Detalles Bibliográficos
Autores principales: Omran, Mervat M., Abdelfattah, Raafat, Moussa, Heba S., Alieldin, Nelly, Shouman, Samia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466443/
https://www.ncbi.nlm.nih.gov/pubmed/32974132
http://dx.doi.org/10.3389/fonc.2020.01348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466443/
https://www.ncbi.nlm.nih.gov/pubmed/32974132
http://dx.doi.org/10.3389/fonc.2020.01348

Ejemplares similares